alexa Hematopoetic-stem-cell Based Therapy For HIV Disease
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Clinical & Cellular Immunology
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Josef Bodor
ScientificTracks Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.017
Abstract
Our goals are to develop insight and understanding of the effect of deleting the chemokine receptor CCR5 in T cells important for HIV entry and its interplay with immune regulation in HIV, forming basis for a novel technology platform to cure HIV disease. A major innovation is the use of hematopoetic stem cell (HSC) transplantation of the cells resistant to HIV such as CCR5∆32 cells, which do not express CCR5 due to a deletion in the promoter. The mutation spontaneously occur in 4-15% of the European population (with frequency remarkably increased in North), confer resistance to HIV in homozygous individuals and could cure HIV disease based on the outcome of bone marrow engraftment in HIV patients with leukemia using a CCR5∆32 homozygous donor. However, patients receiving a bone marrow allotransplantation often suffer from graft- versus-host disease (GvHD), and for that reason HIV infection is not considered an indication, unless leukemia warrants transplantation. To advance this field, it is, however, vital with i) mapping of donors in bone marrow registries to identify CCR5∆32 donors for world-wide matching to HIV+ leukemic recipients; ii) to advance strategies to understand immune dysfunction and immune regulation in HIV and be able to offer suppression of GvHD and iii) to explore function of CCR5∆32 T cells and the possibility to manipulate CCR5 in stem cells moving towards future autotransplantion of CCR5 deleted hematopoetic stem cells. Our approach is to first screen Registries of Bone Marrow Donors in Norway and the Czech Republic and identify donors homozygous for ∆32 mutation. Secondly, in order to ameliorate GvHD, we intend to exploit mechanism of inhibition of interleukin-2 (IL-2) gene expression, which plays a crucial role in repression of CD4+T conventional cells (Tcons) by naturally occurring CD4+CD25+ T regulatory cells (nTregs). Transfer of cyclic AMP (cAMP) from nTregs to Tcons and/ or its receptor-mediated induction in adaptive Tregs underpins function of potent transcriptional repressor termed Inducible cAMP Early Repressor (ICER) leading to suppression of IL-2 synthesis thus reflecting potential suppressive function of T cells during GvHD. Further understanding of the mechanisms of immunological self-tolerance will also provide insights into how strong immune responses such as graft rejection could be restrained and engraftment of HIV resistant cells in HIV+ leukemic patients could be augmented.
Biography
Josef Bodor received his PhD (1990) with honors from Institute of Molecular Genetics in Prague, Czech Republic. As of 2013, he is a Senior Investigator working at the Institute of Experimental Medicine in Prague, Czech Republic. He is a senior scientist with faculty experience from Ivy League Institutions in US hosting on sabbatical leaves around the world (Harvard University Boston, MA, Columbia University; New York, NY, Kyoto University, Kyoto, Japan, W?rzburg University, W?rzburg, Germany, and Johannes Gutenberg University in Mainz, Germany).
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematic[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords